Pulse Biosciences Grants Equity Incentive Awards to New Employees
December 16 2019 - 5:26PM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE) (“Pulse Biosciences” or
the “Company”), a novel bioelectric medicine company bringing to
market its proprietary CellFX™ System, announced today that the
Compensation Committee of the Company’s Board of Directors granted
non-qualified stock options covering an aggregate of 3,000 shares
of Pulse Biosciences common stock to a recently hired non-executive
employee under the Pulse Biosciences 2017 Inducement Equity
Incentive Plan on December 16, 2019.
The 2017 Inducement Equity Incentive Plan is used exclusively to
grant equity awards to individuals who were not previously an
employee or non-employee director of Pulse Biosciences as an
inducement material to such individual’s entering into employment
with Pulse Biosciences in accordance with Nasdaq Marketplace Rule
5635(c)(4).
The options have an exercise price of $14.22 per share, which is
equal to the closing price of Pulse Biosciences common stock on
December 16, 2019. The 3,000 shares underlying the option grants
will vest and become exercisable as to 25% of the shares annually
beginning on the first anniversary of the recipient’s start date,
subject to the recipient’s continued employment with Pulse
Biosciences on these vesting dates. The options are subject to the
terms and conditions of the 2017 Inducement Equity Incentive Plan
and the award agreements entered into with each recipient.
About Pulse Biosciences
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that improves and potentially
extends the lives of patients. The CellFX System is the first
planned commercial product to harness the distinctive advantages of
the Company’s proprietary Nano-Pulse Stimulation™ (NPS™) technology
to treat a variety of applications for which an optimal solution
remains unfulfilled. NPS technology delivers nano-second pulses of
electrical energy to non-thermally clear cells while sparing
adjacent non-cellular tissue. The cell-specific effects of NPS
technology have been validated in a series of ongoing clinical
trials. The CellFX System is preparing to launch as a
multi-application platform designed to address a broad range of
dermatologic conditions. As part of the customer experience, the
Company is offering a utilization-based revenue model and
easy-access customer portal offering a suite of services. CellFX
procedures offer customer value across an expanding spectrum of
clinical applications. The initial commercial use will be in the
clearance of common and difficult-to-treat skin lesions that share
high demand among patients and practitioners for improved and
durable aesthetic outcomes that lead to greater overall
satisfaction.
Caution: Pulse Biosciences’ CellFX System and Nano-Pulse
Stimulation (NPS) technology are for investigational use only.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191216005819/en/
Investor Relations: Pulse Biosciences, Inc. Sandra
Gardiner Executive Vice President and Chief Financial Officer
IR@pulsebiosciences.com
or
Solebury Trout Gitanjali Jain Ogawa, 646-378-2949
gogawa@troutgroup.com
Media: Tosk Communications Nadine D. Tosk, 504-453-8344
nadinepr@gmail.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Sep 2023 to Sep 2024